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Abstract Hepatic encephalopathy that is associated with severe liver failure may compromise
the blood-brain barrier (BBB) integrity. However, the effects of less severe liver diseases, in the
absence of overt encephalopathy, on the BBB are not well understood. The goal of the current
study was to investigate the effects of hepatic ischemia-reperfusion (IR) injury on the BBB tight
junction permeability to small, hydrophilic molecules using the widely used [14C]sucrose and
recently-proposed alternative [13C]sucrose as markers. Rats were subjected to 20 min of hepatic
ischemia or sham surgery, followed by 8 h of reperfusion before administration of a single bolus
dose of [14C] or [13C]sucrose and collection of serial (0-30 min) blood and plasma and terminal
brain samples. The concentrations of [14C] and [13C]sucrose in the samples were determined by
measurement of total radioactivity (nonspecific) and LC-MS/MS (specific), respectively. IR
injury significantly increased the blood, plasma, and brain concentrations of both [14C] and
[13C]sucrose. However, when the brain concentrations were corrected for their respective area
under the blood concentration-time curve, only [14C]sucrose showed significantly higher (30%)
BBB permeability values in the IR animals. Because [13C]sucrose is a more specific BBB
permeability marker, these data indicate that our animal model of hepatic IR injury does not
affect the BBB tight junction permeability to small, hydrophilic molecules. Methodological
differences among studies of the effects of liver diseases on the BBB permeability may confound
the conclusions of such studies.

Keywords Blood-brain barrier permeability . [14C]Sucrose . [13C]Sucrose . Apparent brain
uptake clearance . Hepatic ischemia-reperfusion injury
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Introduction
Acute liver failure is a serious, life-threatening condition that may result in hepatic
encephalopathy, coma, and death (Bernal and Wendon 2013). Although somewhat debatable
(Butterworth 2013), several investigators have reported an increased BBB permeability in
hepatic encephalopathy and coma (Butterworth 2016; Cauli et al. 2011; Chastre et al. 2013; Chen
et al. 2009; Chen et al. 2013; McMillin et al. 2015). However, the effects of less severe hepatic
diseases in the absence of overt encephalopathy or coma, such as hepatic ischemia-reperfusion
(IR) injury, on the BBB permeability have not been well understood.
Our recent studies (Miah et al. 2014) demonstrated that hepatic IR injury increased the
expression of P-glycoprotein (P-gp) at the BBB, resulting in a decrease in the apparent in vivo
brain uptake clearance of the P-gp marker rhodamine 123. Additionally, an in vivo study using
sodium fluorescein (FL) (Miah et al. 2015), as a BBB tight junction permeability marker to small
hydrophilic molecules, indicated that IR significantly increased the brain concentrations of the
marker. However, the brain concentrations corrected for the free drug concentration in plasma
was similar in both groups, suggesting no change in the permeability through the BBB tight
junctions as a result of IR. Because FL might also pass the BBB through some transporters
(Hawkins et al. 2007; Huai-Yun et al. 1998; Loscher and Potschka 2005), the true effects of
hepatic IR on the integrity of BBB tight junctions remain to be determined by using a marker
that is not subject to BBB transporters and is devoid of confounding factors such as binding to
plasma proteins and hepatic metabolism.
Radiolabeled [14C]sucrose is a small (342 Da), hydrophilic molecule with a very low
permeability across the intact BBB, which has no known binding to blood or plasma proteins and
no significant systemic metabolism. Further, no significant facilitative or active transport of
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sucrose in vivo has been demonstrated in mammals to date. Therefore, it has been one of the
most widely used small molecules for quantitative determination of blood-brain barrier (BBB)
integrity in many in vitro (Behrens et al. 2015; Kochi et al. 1999; Oppenheim et al. 2013;
Paulson et al. 2006), in situ brain perfusion (Bickel et al. 1996; Cannon et al. 2012; Hawkins et
al. 2010; Huber et al. 2002; Lochhead et al. 2012; Ronaldson et al. 2009), and in vivo (Bickel et
al. 1998; Chavarria et al. 2010; Ferguson and Woodbury 1969; Jin et al. 2013; Lo et al. 1987;
Ohno et al. 1978; Preston et al. 1984; Preston and Haas 1986; Preston and Webster 2002; Smith
et al. 1988; Stolp et al. 2005; Yin et al. 2008; Ziylan et al. 1983; Ziylan et al. 1984; Ziylan et al.
1988) studies. Very recently (Miah et al. 2017), we demonstrated that the apparent brain uptake
clearance (Kin) of [14C]sucrose in normal rats, estimated by quantitation of total radioactivity in
the brain, was around 6-7 fold higher than that of stable isotope labeled [13C]sucrose, which was
quantitated using a specific LC-MS/MS method. Upon chromatographic fractionation of the
brain samples of rats injected in vivo with [14C]sucrose, several peaks, in addition to the intact
sucrose, were identified. Although the possibility of a minor systemic metabolism could not be
ruled out, the higher Kin values for [14C]sucrose were attributed, at least in part, to presence of
small lipophilic impurities in the stock solution of [14C]sucrose, which could easily penetrate
BBB. Therefore, it was suggested that specific quantitation of the stable isotope (13C) of sucrose
is a more accurate alternative to the current widespread use of the radioactive sucrose as a BBB
permeability marker.
The main objective of the current study was to investigate the effects of hepatic IR on the
BBB permeability to sucrose using the specific [13C]sucrose marker. Although [14C]sucrose
substantially overestimates the absolute permeability of BBB to sucrose, it may still be a valid
marker in studies of the effects of a disease state on the BBB permeability when its brain uptake
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clearance is compared in healthy and diseased conditions. Therefore, a secondary objective of
the study was to test whether the use of [14C]sucrose would affect the conclusion of such studies.

Materials and methods
Chemicals and reagents
We purchased [UL-13C12]sucrose (all the carbons in both glucose and fructose molecules are
labeled with
13

13

C isotope; denoted [13C]sucrose) and the internal standard (IS), which was [UL-

C6fru]sucrose (all the carbons in the fructose molecule are labeled with

13

C isotope), from

Omicron Biochemicals (South Bend, IN, USA). [14C]Sucrose, Solvable, and Hionic-Fluor
solution were purchased from PerkinElmer (Boston, Massachusetts, USA). Specific activity of
the [14C]sucrose stock solution was 400-700 mCi/mmol. 3H-Labelled rat serum albumin (RSA)
was prepared and chromatographically purified as described before (Bickel et al. 1998). The
precipitability by trichloroacetic acid of the purified 3H-RSA peak was greater than 98%. LC-MS
grade water (J.T. Baker) was purchased from Avantor Performance Materials, Inc. (Center
Valley, PA, USA). Analytical grade ammonium hydroxide and LC-MS grade acetonitrile (ACN)
were purchased from Fisher Scientific (Fair Lawn, NJ, USA). For anesthesia, ketamine and
xylazine solutions were purchased from Lloyd Laboratories (Shenandoah, IA, USA). Heparin
solution was purchased from APP Pharmaceuticals (Schaumburg, IL, USA). All other chemicals
were analytical grade and obtained from commercial sources.
Animals
Adult, male Sprague-Dawley rats were purchased from Charles River laboratory (Wilmington,
MA) and acclimated in single, ventilated cages with 12-h dark-light cycles in a temperature- and
humidity-controlled room with free access to the food and water. All the animal procedures used
in this study were approved by Texas Tech University Health Sciences Center’s Institutional
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Animal Care and Use Committee and were consistent with the guidelines set by the Guide for the
Care and Use of Laboratory Animals (National Research Council, 2011). Animals were
randomly assigned to two experimental groups of [14C] and [13C]sucrose, which were further
divided into two groups of sham surgery (Sham) and IR, resulting in a total of 4 groups (n = 57/group). The average ± SD of body weights (g) of animals were 306 ± 12 (Sham) and 298 ± 14
(IR) for the [13C]sucrose groups and 287 ± 3 (Sham) and 276 ± 13 (IR) for the [14C]sucrose
groups.
Hepatic ischemia-reperfusion (IR) injury model
To determine whether the use of [13C]sucrose or [14C]sucrose would affect the outcome of BBB
permeability studies in a disease model, the BBB permeability to [13C] and [14C]sucrose was
determined in different groups of rats subjected to hepatic IR or sham surgery (Sham), as
described before (Miah et al. 2015). Briefly, after an overnight fast, rats were anesthetized with
ketamine: xylazine (80:8 mg/kg) via intramuscular injection. For the IR group, after opening the
abdomen, the blood supply to the entire liver was occluded by placing a microvascular clamp on
the portal triad. Complete obstruction of blood flow to the liver was confirmed by visual
inspection of the liver color. After 20 min of total hepatic ischemia (Pringle maneuver), the liver
was reperfused with blood by removing the clamp. Finally, 5 ml of normal saline (37ᴼC) was
added to the abdominal cavity to compensate for the loss of fluids during the surgery, and the
muscle and skin layers were closed. During the entire procedure, the rat body temperature was
maintained at 37ᴼC by using a heating lamp and a heating plate attached to a rectal temperature
control probe. Sham animals underwent only laparotomy under identical experimental conditions
but without any interruption of the blood supply to the liver. Rats were allowed to recover for 8 h
before dosing with the markers.
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Dosing and sampling
After 8 h of reperfusion, rats were anesthetized with ketamine: xylazine at a dose of 80:4 mg/kg.
Subsequently, a catheter was placed into the femoral artery for the collection of blood samples.
For the [13C]sucrose study, a single 10-mg/kg dose of the marker was administered as a bolus
dose (via penile vein). For the [14C]sucrose study, the bolus dosing solution contained 3 µCi (~
6.5 µg/kg) of the marker plus 10 µCi of 3H-RSA, as the vascular marker. Our recent report (Miah
et al. 2017) indicated that the dose-corrected plasma/blood disposition of both markers were
similar despite significant differences between the absolute doses of the two markers. Serial
blood samples (~0.2 ml) were then collected for 30 min, a portion was centrifuged for collection
of plasma and another portion was used for measurement of blood concentrations. Each time
after collection of blood samples, the catheter was filled with heparin (10 U/ml) to prevent blood
clotting. To remove the residual blood from the brains of animals injected with [13C]sucrose, at
the end of sampling a catheter was placed in the left ventricle, and the whole body was perfused
with ice-cold saline at a rate of 25 ml/min for 5 min. Finally, brain was collected from both
groups and snap frozen in cold iso-pentane. All samples were kept at

-80ᴼC until analysis.

LC-MS/MS analysis of [13C]sucrose
Before analysis of [13C]sucrose by LC-MS/MS, plasma and blood samples were diluted 100- and
50-fold, respectively, and brain samples were homogenized in water (1:9). The LC-MS/MS
method is described in a recent publication (Miah et al. 2016). In brief, brain homogenates and
diluted plasma and blood samples (20 µl) were subjected to protein precipitation by the addition
of 180 µl of acetonitrile: water (80:20), which also contained IS. Chromatographic separation
was then performed using an Acquity BEH amide column (50 mm х 3 mm, 1.7 µm) and an
isocratic mobile phase of acetonitrile: water: ammonium hydroxide (72:28:0.1, v/v), run a flow
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rate 0.2 ml/min. Column temperature was maintained at 45oC, and autosampler was at room
temperature. The retention time of sucrose was ~2.5 min, and the total run time was 6 min. The
MRM was monitored in negative mode, and the transitions for [13C]sucrose and IS were 353à92
m/z and 347à89 m/z, respectively.
Liquid scintillation analysis of [14C]sucrose and [3H]-RSA
For [14C] and [3H] analysis, one hemisphere of the brain was cut into small pieces, and 0.2-0.3 g
of the brain tissue was added to 2 ml of Solvable to digest the tissue. Additionally, 20 µl of blood
and plasma samples were added to 2 ml of solvable. After 24 h at room temperature, 100 µl of
hydrogen peroxide was added to each sample to remove any possible color quenching, 12 ml of
scintillation fluid was added, and the samples were subjected to the scintillation counter.
Analysis of AST and ALT
Plasma AST and ALT levels were measured to confirm the IR-induced hepatic damage by a kit
from TECO diagnostics (Anaheim, CA), according to the manufacturer’s protocol.
Pharmacokinetic analysis
Apparent brain uptake clearance (Kin) values were estimated after a 30-min sampling period for
both plasma (Kin-plasma) and blood (Kin-blood) AUC data (Gjedde 1981):
𝐾"#$%&''( =
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are the amount of the marker in the terminal (30 min)

brain sample (in units of mass/g of brain) and the areas under the blood or plasma concentration%&''(
time curve from time zero to the last sampling time (30 min), respectively. The 𝐴𝑈𝐶?$>?
and
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were estimated by non-compartmental analysis of the concentration-time data during
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the sampling period (5-30 min) using the log-linear trapezoidal method in Phoenix®
WinNonlin® software (Certara, Princeton, NJ). The method back extrapolates the concentration
%@
at time zero for AUC calculations (AUC0-30). For [13C]sucrose, 𝐶>?
was the brain concentration
%@
of the marker after the in situ removal of the residual blood in the brain. For [14C]sucrose, 𝐶>?

was the brain concentration of the marker after correction for the residual contents of the
radioactivity in the brain vasculature estimated using the following equations:
%@
%@CD67E
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are the total (brain tissue plus vasculature)

brain amount of [14C]sucrose per g of tissue, volume of blood or plasma within the brain
vasculature, and blood or plasma concentrations of [14C]sucrose at 30 min, respectively. 𝑉%&''(
and 𝑉5&6786 were estimated from the 3H-RSA data:
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concentrations of 3H-RSA. Similar to the sucrose data, the 𝐴𝑈𝐶?$>?
and 𝐴𝑈𝐶?$>?

values for

RSA were also estimated using the log-linear trapezoidal method in Phoenix® WinNonlin®
software.
To allow comparison of data between the [13C] and [14C]sucrose, the mass of the markers
in the blood and brain were corrected for the injected dose and expressed as percentage of
injected dose (%ID).

9

Statistical analysis
Comparison of two means for the IR and Sham groups was carried out by an unpaired, two-tailed
Student’s t-test. For ALT and AST measurements, two-way ANOVA, followed by Bonferroni
post-hoc analysis was used. A p value of < 0.05 was considered significant. Data are presented as
mean ± SD or individual values.

Results
Plasma concentrations of the hepatic IR injury markers are presented in Fig. 1. As demonstrated
in this figure, hepatic IR injury significantly increased the plasma levels of ALT (Fig. 1a) and
AST (Fig. 1b) in the IR animals, as compared with their respective Sham groups. Comparison of
ALT or AST values across the two sucrose marker groups showed no significant differences
between the two marker groups for AST (Fig. 1b). However, the ALT levels in the [14C]sucroseIR group were significantly (p < 0.01) lower than those for the [13C]sucrose-IR group (Fig. 1a).
The plasma and blood concentration-time courses of the vascular marker 3H-labeled rat
serum albumin (3H-RSA) in the Sham and IR groups are presented in Fig. 2, and the
corresponding zero to 30 min AUC (AUC0-30) values and vascular volumes are presented in
Table 1. IR caused a significant increase in the blood and plasma concentrations (Fig. 2) and
AUC0-30 values (Table 1) of 3H-RSA. However, there were no changes in the blood or plasma
vasculature volume of the brain because of the IR injury (Table 1). On average, the brain plasma:
blood volume ratios were 0.54 and 0.51 (Table 1) for the Sham and IR groups, suggesting
hematocrit values of 0.46 and 0.49, respectively.
The plasma and blood concentrations-time profiles of [14C] and [13C]sucrose in the IR
and Sham animals are depicted in Figure 3, and their corresponding AUC0-30 values are
presented in Figure 4. The plasma and blood concentrations of [13C]sucrose (Figs. 3a and 3b) and
10

[14C]sucrose (Figs. 3c and 3d) followed similar patterns, suggestive of multicompartment
disposition. Additionally, for both markers, the plasma concentrations (Figs. 3a and 3c) were
higher than the corresponding concentrations in blood (Figs. 3b and 3d), which is in agreement
with the lack of penetration of sucrose to the red blood cells. Further, the blood and plasma
concentrations (Fig. 3) and AUC0-30 values (Fig. 4) of both markers in the IR animals were
significantly higher than those in the Sham animals.
The terminal brain concentrations of [13C] and [14C]sucrose in the IR and Sham animals
are presented in Fig. 5. Although the brain concentrations of both markers were higher in the IR
animals, only for [14C]sucrose did the difference between the Sham and IR groups reach
statistical significance (p = 0.0026, Fig. 5b); the p value for the difference between the Sham and
IR groups for the brain concentrations of [13C]sucrose was 0.0502. Apparent brain uptake
clearance (Kin) of [13C] (Figs. 6a and 6b) and [14C]sucrose (Figs. 6c and 6d), based on the plasma
(Figs. 6a and 6c) or blood (Figs. 6b and 6d) AUC0-30 values, are presented in Fig. 6. There were
no significant differences in the plasma or blood Kin values between the Sham and IR groups for
[13C]sucrose (Figs. 6a and 6b). However, blood Kin values for [14C]sucrose were significantly (p
= 0.0163 ) higher in the IR animals, compared with the Sham group (Fig. 6d).

Discussion
In this study, we examined the effects of hepatic IR injury on the permeability of BBB tight
junctions to sucrose using an animal model of Pringle maneuver (total hepatic ischemia) that is
used clinically during liver surgery for trauma, resection of cancerous tissue, or liver
transplantation. A significant increase in the plasma concentrations of the liver injury markers,
ALT and AST, in both [13C] and [14C]sucrose groups (Fig. 1) confirmed the IR injury.
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IR injury increased the plasma and blood concentrations and AUC0-30 values of the
vascular marker RSA (Fig. 2 and Table 1) and those of both [13C] and [14C]sucrose (Figs. 3 and
4). The higher blood or plasma concentrations of [13C] and [14C]sucrose in the IR animals were
also reflected in higher brain concentrations for both markers (Fig. 5), although the IR-induced
increase in the brain concentrations of [13C]sucrose barely missed the significance level (p =
0.0502). When the terminal brain concentrations of the markers were corrected for their
corresponding blood or plasma AUC0-30 values, the Kin-blood values were significantly increased
by 30% only in the case of [14C]sucrose (Fig. 6). Therefore, whereas the [13C]sucrose data do not
suggest any changes in the BBB permeability to sucrose as a result of hepatic IR, the opposite is
true based on the Kin-blood values of [14C]sucrose (Fig. 6).
Accurate measurement of brain concentrations of BBB markers with low permeability
requires removal of the blood content of brain by perfusion or the use of a vascular marker to
eliminate the contribution of brain blood to the total brain concentrations of the marker.
Consequently, [14C]sucrose is frequently used along with radioactive albumin as a vascular
marker, a method that was also used in our studies. For the [13C]sucrose, we chose to remove the
brain blood by perfusion before collection of brain, in order to avoid the use of radioactive
vascular markers. It may be argued that the differences between the two methods might be due to
residual blood after the brain perfusion in the [13C]sucrose group. However, any residual blood in
the brain of rats injected with [13C]sucrose is expected to cause an increase in the Kin value of
[13C]sucrose, compared with that in the [14C]sucrose group, which is opposite of our
observations (Fig. 6).
The injection of RSA in the [14C]sucrose group allowed us to estimate the volumes of
brain plasma and blood, which were 8.99 and 16.6 µl/g, respectively, in the Sham animals (Table
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1), predicting a cerebral hematocrit of 0.46 in this group. These values are in agreement with the
cerebral blood volume of 25.1 µl/g, measured by the summation of red blood cell volume (99mTclabelled red blood cells) and plasma volume ([14C]dextran), and a hematocrit of 0.43 in control
rats (Todd et al. 1992). The estimated hematocrit in the brain blood (0.46) of our Sham animals
is also close to the estimated hematocrit in the systemic blood (0.47) in the same group, with the
latter obtained from the RSA blood and plasma AUC0-30 values (Table 1). The Vblood and Vplasma
values for the IR animals were not significantly different from those in the Sham animals (Table
1), suggesting that our IR model does not affect the cerebral blood or plasma volumes.
The lack of a significant effect of a 20-min Pringle maneuver plus 8 h of reperfusion on
the [13C]sucrose Kin (Figs. 6a and 6b) is in agreement with our recent study using sodium
fluorescein (FL) as a BBB permeability marker in the same disease model (Miah et al. 2015).
Similar to sucrose, FL is a small, hydrophilic, low MW (374 Da) marker, which minimally
crosses the intact BBB. However, the use of FL is subject to some inherent confounding
problems, including disease state-induced potential changes in the protein binding of the marker.
For example, when the Kin value of FL was estimated based on Eq. 2 using the total (free plus
unbound) AUC0-30 of FL, hepatic IR significantly increased the marker’s Kin. However,
correcting for the free fraction of the marker in the plasma, the Kin values in the Sham and IR rats
were similar (Miah et al. 2015). In addition to the problem of binding to plasma proteins, some
investigators have suggested that FL might pass the BBB through some transporters (Hawkins et
al. 2007; Huai-Yun et al. 1998; Loscher and Potschka 2005). Therefore, [14C]sucrose, because of
its lack of binding to plasma proteins and lack of any known transporters for its passage through
the mammalian BBB, has so far been considered a more advantageous low MW marker for the
BBB permeability. However, our current study indicates that the use of [14C]sucrose might also
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result in inaccurate conclusions regarding the changes in the BBB permeability in pathological
conditions.
Previous studies and our own recent investigation (Miah et al. 2017) suggest presence of
minor (a few percentages) lipophilic impurities in the stock solutions of [14C]sucrose. Although
these impurities do not significantly affect the plasma or blood AUC of the total radioactivity,
they can account for a significant portion of the total radioactivity count in the brain. This is
because these lipophilic impurities can penetrate BBB to a much greater magnitude, compared
with the almost impenetrable intact [14C]sucrose. Consequently, the Kin values of [14C]sucrose in
control animals were, on average, ~7 fold higher than that of [13C]sucrose, which was quantitated
by a specific LC-MS/MS method that only measures the intact marker (Miah et al. 2017). Our
current observation that the Kin values were significantly increased in the IR animals only in the
case of [14C]sucrose suggests that the IR injury differentially affects the pharmacokinetics of the
impurities in the [14C]sucrose and the intact [14C]sucrose itself. For example, if IR injury
increases the AUC of the impurities more than the AUC of the intact [14C]sucrose, the more than
proportionate increase in the AUC of the impurities, relative to that of the intact [14C]sucrose,
significantly increases the brain concentration of the total radioactivity without a significant
effect on the total AUC itself, resulting in a higher Kin value for [14C]sucrose.
The increase in the plasma and blood concentrations (Fig. 3) and AUC0-30 values (Fig. 4)
of both [13C] and [14C]sucrose in IR animals suggest a decrease in the clearance of sucrose as a
result of IR injury. Sucrose is almost completely eliminated by excretion of the unchanged drug
in the urine through glomerular filtration (Winkler and Parra 1937). Because hepatic IR injury is
known to decrease the renal function (Behrends et al. 2008; Lee et al. 2009; Lee et al. 2011), the
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apparent decrease in the clearance of sucrose in the IR animals is most likely due to a reduced
renal function in these animals.

Conclusions
Hepatic IR injury increased the plasma, blood, and brain concentrations of BBB permeability
markers [13C] and [14C]sucrose in rats. However, the apparent brain uptake clearance, which is
estimated from the brain concentrations corrected for blood AUC, was increased significantly
after IR only in the case of [14C]sucrose. Therefore, although [14C]sucrose data indicated that
hepatic IR injury significantly increases the BBB permeability, this conclusion was not
supported by the [13C]sucrose data. Because [13C]sucrose is a more specific BBB permeability
marker (Miah et al. 2016; Miah et al. 2017), these data indicate that our model of hepatic IR
injury does not affect the BBB tight junction permeability to small, hydrophilic molecules.
Further, nonspecific measurement of [14C]sucrose by total radioactivity may result in an
erroneous conclusion regarding disease state-induced alterations in the BBB permeability to
small molecules.
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Figure Legends
Fig. 1 Plasma concentrations of ALT (a) and AST (b) in [13C] and [14C]sucrose groups. Different
groups of animals (n = 5-7/group) were subjected to 20 min of Pringle maneuver (total hepatic
IR) or sham surgery, and plasma concentrations of ALT and AST were measured 8 h after
reperfusion. Columns and bars represent mean and SD values, respectively. Statistical
significance (p value) is based on two-way ANOVA, followed by Bonferroni post-hoc analysis.
Fig. 2 Plasma and blood concentration-time courses of [3H]-RSA in the IR and Sham animals.
Different groups of animals (n = 5/group) were subjected to 20 min of Pringle maneuver (total
hepatic IR) or sham surgery, followed by 8 h of reperfusion. A single intravenous dose of [3H]RSA (10 µCi) was administered, and serial blood and plasma samples were obtained. Symbols
and bars represent mean and SD values, respectively.
Fig. 3 Plasma (a and c) and blood (b and d) concentration-time courses of [13C] (a and b) and
[14C] (c and d) sucrose in the IR and Sham animals. Different groups of animals (n = 5-7/group)
were subjected to 20 min of Pringle maneuver (total hepatic IR) or sham surgery, followed by 8
h of reperfusion. A single intravenous dose of [13C]sucrose (10 mg/kg) or [14C]sucrose (3 µCi)
was administered, and serial blood and plasma samples were obtained. Symbols and bars
represent mean and SD values, respectively.
Fig. 4 Plasma (a and c) and blood (b and d) AUC0-30 of [13C] (a and b) and [14C] (c and d)
sucrose in the IR and Sham animals. Different groups of animals (n = 5-7/group) were subjected
to 20 min of Pringle maneuver (total hepatic IR) or sham surgery, followed by 8 h of reperfusion.
A single intravenous dose of [13C]sucrose (10 mg/kg) or [14C]sucrose (3 µCi) was administered,
and serial blood and plasma samples were obtained. Symbols and vertical lines represent
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individual and mean values, respectively. Statistical significance (p value) is based on unpaired,
two-tailed Student’s t-test.
Fig. 5 Terminal brain concentrations of [13C] (a) and [14C] (b) sucrose in the IR and Sham
animals. Different groups of animals (n = 5-7/group) were subjected to 20 min of Pringle
maneuver (total hepatic IR) or sham surgery, followed by 8 h of reperfusion. A single
intravenous dose of [13C]sucrose (10 mg/kg) or [14C]sucrose (3 µCi) was administered, and brain
was collected at 30 min. Symbols and vertical lines represent individual and mean values,
respectively. Statistical significance (p value) is based on unpaired, two-tailed Student’s t-test.
Fig. 6 Plasma (a and c) and blood (b and d) Kin values of [13C] (a and b) and [14C] (c and d)
sucrose in the IR and Sham animals. Different groups of animals (n = 5- 7/group) were subjected
to 20 min of Pringle maneuver (total hepatic IR) or sham surgery, followed by 8 h of reperfusion.
A single intravenous dose of [13C]sucrose (10 mg/kg) or [14C]sucrose (3 µCi) was administered,
and serial blood and plasma samples and terminal brain samples were obtained. Symbols and
vertical lines represent individual and mean values, respectively. Statistical significance (p value)
is based on unpaired, two-tailed Student’s t-test.
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Table 1 Plasma and blood AUC0-30 values and brain volume of distribution (V) values (mean ±
SD) of 3H-RSA in Sham and IR rats. Animals in each group (n = 5/group) received a single
intravenous dose of 3H-RSA (10 µCi), and serial blood samples were taken over 30 min.

Parameter

Plasma
Sham

AUC0-30, %ID.min/ml

307 ± 32

Blood
IR
**

410 ± 57
8.40 ± 1.10

Sham

IR

164 ± 19

198 ± 16*
16.6 ± 3.1

8.99 ± 1.03
16.6 ± 1.1
V, µl/g
p < 0.05, ** p < 0.01: Significantly different from the Sham group based on unpaired, two-tailed
Student’s t-test.
*
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